Search PubMed⌕ Search

Biomedical subjects

L A Goriachkina

Publications and source records attributed to L A Goriachkina.

At least 19 recordsLinked to original sources
PubMed2002

A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia.

BACKGROUND: In Russia, current therapy for the long-term management of asthma is mainly nonsteroidal. This situation provides the opportunity to evaluate new asthma treatments in a patient cohort with little previous exposure to inhaled corticosteroids. OBJECTIVES: To compare the effect of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone, on the health-related quality of life (HRQL) of patients with mild to moderate asthma. METHODS: A double-blind, parallel-group, randomized, 12-week study compared formoterol Turbuhaler plus budesonide Turbuhaler and budesonide Turbuhaler alone with an open control group of the investigator's choice of noncorticosteroid therapy. Patients completed the Short Form 36 (SF-36) and the Asthma Quality of Life Questionnaire (AQLQ). RESULTS: The improvement in HRQL scores for patients treated with noncorticosteroids was significantly less (p < 0.05) than those treated with formoterol plus budesonide and budesonide alone in all domains of the SF-36 and AQLQ with one marginal exception (budesonide versus investigator's choice, SF-36, Mental Component Scale, p = 0.053). Improvements in HRQL scores of formoterol plus budesonide, compared with budesonide alone, although generally higher, were not significantly different. Formoterol plus budesonide was more effective in improving lung function and reducing both symptoms and the need for relief terbutaline inhalation. CONCLUSION: Formoterol Turbuhaler plus budesonide Turbuhaler and budesonide Turbuhaler alone significantly improved the HRQL of patients with mild to moderate asthma compared with noncorticosteroid treatment.

Administration, Inhalation↗
PubMed1998

[Ebastine in the treatment of seasonal allergic rhinitis].

AIM: To test the efficiency and tolerance of the second generation antihistamine drug ebastin (kestine) in patients with seasonal allergic rhinitis (SAR). MATERIALS AND METHODS: Kestin was given for 3 weeks in doses 10 and 20 mg/day to 226 patients with SAR running for 6.8 +/- 6.1 years. SAR symptoms relief, subjective effects, side effects were studied. RESULTS: The total index of rhinitis symptoms diminished from 11.6 to 1.2 scores. Subjective response was registered in 82% of the patients, objective in 77%. Neither treatment aggravations nor serious side effects occurred. 2 patients had drowsiness, head aches, dizziness and discontinued treatment. CONCLUSION: Kestin is effective in SAR, had no serious side effects, is well tolerated.

Administration, Oral↗
PubMed1994

[Comparative study of the effectiveness of equivalent doses of the preparation ditek, disodium cromoglycate and fenoterol in atopic bronchial asthma].

18-45-year-old patients with atopic bronchial asthma free of associated inflammatory diseases received ditek, lomudal and berotek (28, 10 and 10 patients, respectively). Biochemical assessment of allergic inflammation activity demonstrated that ditek is most effective of the above three drugs both in relation to induction of clinical remission and to inhibition of allergic inflammation.

Adolescent↗
PubMed1987

[Characteristics of 2 clinico-pathogenetic variants of the atopic form of bronchial asthma].

IgE- and IgG-reagins were investigated in the sera of 120 patients with atopic bronchial asthma. Two clinicopathogenetic variants of disease were defined with relation to the genetic variants of disease were defined with relation to the main immunological mechanism: IgE-dependent (in 78 patients) and IgE-IgG-dependent (in 42 patients). Variations in a clinical picture, the results of specific allergological examination, the level of total serum IgE in different variants of the atopic form of bronchial asthma were established. Specific immunotherapy produced a good effect in the IgE-dependent variant. In the patients with the IgE-IgG-dependent variant specific immunotherapy with a house dust allergen proved to be ineffective in most cases.

Adolescent↗
PubMed1980

[Experimental study of the allergenic activity of the pollen of Cyclachena xanthifolia].

Comparative studies of Cyclachena xantifolia and Ambrosia artemisifolia have been carried out by light, scanning and electron microscopy. Cyclachena xantifolia allergic properties have been examined in guinea-pigs. Senstization of animals has caused the increased number of immunocompetent cells in regional and distant lymph nodes, the appearance of high titers of reagin-like antibodies capable of fixing in the skin. Injection of the proper dose of allergen has resulted in the development of anaphylactic shock of different severity. The role of Cyclachena xantifolia in the etiology of pollinoses has been ascertained.

Allergens↗